「by」の検索結果
76件：71～75件目を表示
-
d. (Headquarters: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and developed by Senju as an eye drop treatment for Dry Eye Disease (DED), has been launched in Japan today. Avare...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406.pdf -
eric Name: Motugivatrep, development code: SJP-0132, hereinafter: Product), discovered and licensed by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; here...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
d. (Headquarters: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and developed by Senju as an eye drop treatment for Dry Eye Disease (DED), has been launched in Japan today. Avare...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406_0.pdf -
eric Name: Motugivatrep, development code: SJP-0132, hereinafter: Product), discovered and licensed by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; here...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
Product Development Policy | Research & Development | SENJU Pharmaceutica
QOV (Quality of Vision) of patients worldwide. We launched senile cataract drugs in 1958, followed by a series of other products including antimicrobial ophthalmic solutions, non-steroidal anti-infla...
http://www.senju.co.jp/english/rd/policy/